PENTA-ID

what's new

Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial is now published

The paper: Weekends-off efavirenz-based antiretroviral therapy in HIV-infected children, adolescents and young adults (BREATHER): a randomised, open-label, non-inferiority, phase 2/3 trial is now published.

Click

The 1st patient was screened in SMILE in Spain

We are happy to announce that the first patient was screened in SMILE in Spain. We encourage all the sites to follow.

PENPACT1 paper was cited as a basis for changing U.S. Department of Health and Human Services guidelines on pediatric antiretroviral therapy

The PENPACT1 paper titled "Using CD4 percentage and age to optimize pediatric antiretroviral therapy initiation" was cited (along with the adult START trial) as a basis for changing U.S. Department of Health and Human Services guidelines on pediatric antiretroviral...

The Article Children and young people with perinatal HIV in Europe: Epidemiological situation in 2014 and implications for the future is out

The Article "Children and young people with perinatal HIV in Europe: Epidemiological situation in 2014 and implications for the future" is out.

Click here to...

PED-MERMAIDS Study Protocol approved in Spain

We are glad to inform you that the protocol of PED-MERMAIDS study has received the first Ethics approval in Spain.
The PENTA Foundation is the sponsor of the study, which is financed by the European Union 7th Framework Programme within the project PREPARE.

Neurocognition and quality of life after reinitiating antiretroviral therapy in children randomized to planned treatment interruption accepted for publication in AIDS

Ananworanich J, Melvin D, Ramos Amador JT, Childs T, Medin G, Boscolo V, Compagnucci A, Kanjanavanit S, Montero S, Gibb DM, on behalf of the PENTA 11 study group. "Neurocognition and quality of life after reinitiating antiretroviral therapy in children randomized to...

PED-MERMAIDS study ready for submissions to Ethics Committees

We are glad to communicate that the process of submission to Ethics Committees of the study PED-MERMAIDS is about to start in UK, Greece, France, Spain, Portugal, Switzerland and Germany.

Combacte-Magnet: EVADE, a further step in the development of MEDI3902 compound

It is with great pleasure that the COMBACTE-MAGNET WP4A team announce the new name for the phase 2 Proof-of-Concept safety and efficacy study of MEDI3902 in patients at high risk of developing Pseudomonas aeruginosa pneumonia: EVADE (Effort to Prevent Nosocomial...

The Penta Steering Committee took place in Paris on 16th and 17th December 2015.

The Penta Steering Committee took place in Paris on 16th and 17th December 2015.

Thank you all for coming and for your contribution to the meeting. See you next year!

Click here to see the EPPICC Meeting...

The article PENTA: Once- versus twice-daily lopinavir/ritonavir in HIV-1 infected children is out

The article PENTA: Once- versus twice-daily lopinavir/ritonavir in HIV-1 infected children: a randomised controlled trial (KONCERT/PENTA18/ANRS150) has been published in AIDS.

Click here to see the paper